Cantor Fitzgerald set a $80.00 price objective on Zoetis (NYSE:ZTS) in a research report released on Tuesday morning. The firm currently has a buy rating on the stock.

Several other research analysts also recently issued reports on ZTS. Cowen set a $70.00 target price on shares of Zoetis and gave the stock a buy rating in a research note on Thursday, August 24th. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the stock a buy rating in a research note on Friday, August 25th. Stifel Nicolaus reiterated a buy rating and issued a $65.00 target price on shares of Zoetis in a research note on Friday, September 1st. BidaskClub upgraded shares of Zoetis from a buy rating to a strong-buy rating in a research note on Tuesday, September 12th. Finally, Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $71.00 target price on the stock in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company. Zoetis presently has a consensus rating of Buy and an average target price of $68.53.

Shares of Zoetis (NYSE:ZTS) opened at $72.23 on Tuesday. The firm has a market cap of $34,972.68, a PE ratio of 32.92, a price-to-earnings-growth ratio of 2.15 and a beta of 1.06. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a fifty-two week low of $50.57 and a fifty-two week high of $72.79.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.52 earnings per share. equities analysts expect that Zoetis will post 2.37 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be given a dividend of $0.126 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.70%. Zoetis’s dividend payout ratio is 22.11%.

A number of institutional investors have recently modified their holdings of the stock. AXA lifted its position in Zoetis by 15.2% during the third quarter. AXA now owns 252,241 shares of the company’s stock valued at $16,083,000 after purchasing an additional 33,227 shares during the period. Steward Partners Investment Advisory LLC bought a new position in Zoetis during the third quarter valued at approximately $114,000. Garde Capital Inc. bought a new position in Zoetis during the third quarter valued at approximately $419,000. Cetera Advisors LLC bought a new position in Zoetis during the third quarter valued at approximately $211,000. Finally, Yellowstone Partners LLC bought a new position in Zoetis during the third quarter valued at approximately $694,000. Institutional investors own 93.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zoetis (ZTS) Given a $80.00 Price Target by Cantor Fitzgerald Analysts” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/zoetis-zts-given-a-80-00-price-target-by-cantor-fitzgerald-analysts/1761269.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with Analyst Ratings Network's FREE daily email newsletter.